Our journey started with NovaTears®, the first water-free eye drop based on EyeSol® for the treatment of dry eye.
Novatears® is CE certified since 2014 and successfully commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears™ by Ursapharm.
As the first-of-its kind, NovaTears® offers a new Mode of Action by acting as a lubricating lipid layer stabilizer and evaporative barrier for improving tear film stability and quality.
NovaTears® is clinically validated by significant improvement in signs and symptoms in patients with evaporative dry eye disease and Meibomian Gland Disfunction MGD in a number of clinical trials.
Our products target key drivers of the disease and have constantly demonstrated significant improvement in sign and symptoms of dry eye in clinical trials.